DCMNext

DCMNextTM is a targeted panel for patients with dilated cardiomyopathy (DCM).  Often, DCM can be asymptomatic and sudden death is the first and only symptom. Therefore, genetic testing may be the most effective way of identifying at-risk individuals, or confirming a diagnosis.

Downloads

Quick Reference
Test Code 8884
Turnaround Time (TAT) 4-5 weeks
Number of Genes 36
Specimen Requirements Click here

Ordering Options

Why Is This Important?

Knowing if your patient has a hereditary cardiovascular disorder can help you determine their future cardiovascular disease risks and guide your medical management recommendations. Key benefits include:

  1. Clarify diagnosis and risk for sudden cardiac arrest
  2. Target medical management and prevention of cardiac arrest and other complications
  3. Adjust management in those with DCM due to a specific cardiac genotype, or underlying conditions like Duchenne muscular dystrophy and Danon disease
  4. Confirm diagnosis and identify inherited mutation following a sudden death with autopsy findings that indicate DCM.
  5. Offer family members genetic testing (for a familial mutation) and implement medical surveillance to only those that need it
  6. Reduce healthcare costs, resources, and anxiety for families

Mutation Detection Rate

30-40% of patients with non-ischemic DCM have a mutation in one of the DCMNext genes (clinical sensitivity).  DCMNext can detect >99.9% of described mutations in the included genes, when present (analytic sensitivity).

Test Description

DCMNext includes 36 genes that cause DCM (listed above). These genes are also included in the comprehensive cardiomyopathy (CMNext) and cardiovascular genetics (CardioNext) panels. Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized kit and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes, followed by polymerase chain reaction (PCR) and NGS. Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.  This assay targets all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. Gross deletion/duplication analysis for 35 genes is performed utilizing a targeted chromosomal microarray (for all except TXNRD2).

View Full Menu

Search Results

Start your search...